<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334853</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP223</org_study_id>
    <nct_id>NCT01334853</nct_id>
  </id_info>
  <brief_title>A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma</brief_title>
  <official_title>A Prospective Observational Study to Assess the Role of Selected Biomarkers in Subjects Requiring Daily Medium- to High-dose Inhaled Corticosteroids for Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for conducting this study is to explore potential clinical and peripheral
      biomarkers in subjects requiring daily medium to high dose inhaled corticosteroids for
      persistent asthma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To identify an optimal prediction rule for classifying sputum eosinophilic and non-eosinophilic asthmatics.</measure>
    <time_frame>8 Days</time_frame>
    <description>Variables representing lung function tests, patient reported outcomes, and blood biomarkers will be evaluated singly and in various combinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess which markers are associated with sputum eosinophils.</measure>
    <time_frame>8 Days</time_frame>
    <description>Comparing lung function tests between eosinophilic and non-eosinophilic subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess which markers are associated with sputum eosinophils</measure>
    <time_frame>8 Days</time_frame>
    <description>Comparing blood biomarkers between eosinophilic and non-eosinophilic subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess which markers are associated with sputum esonophils</measure>
    <time_frame>8 Days</time_frame>
    <description>Comparing sputum biomarkers bewteen eosinophilic and non-eosinophilic subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess which markers are associated with sputum eosinophils.</measure>
    <time_frame>8 Days</time_frame>
    <description>Comparing patient reported outcomes between eosinophilic and non-eosinophilic subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate transcript expression profiles in whole blood and/or sputum using microarray analyses</measure>
    <time_frame>8 Days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>50 eosinophilic subjects to be evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>50 non-eosinophilic subjects to be evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No drug will be used</intervention_name>
    <description>Biomarker</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No drug will be used</intervention_name>
    <description>Biomarker</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and Sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with asthma on stable medium- to high-dose inhaled corticosteroids.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 through 75 at the time of screening

          -  Written informed consent and any locally required authorization obtained from the
             subject prior to performing any protocol-related procedures, including screening
             evaluations

          -  History of physician-diagnosed asthma for at least 12 months prior to screening

          -  Stable Medium- to high-dose ICS divided twice daily as outlined by the NHLBI Asthma
             Guidelines, 2007

        Exclusion Criteria:

          -  Any medical condition that, in the opinion of the investigator or medical monitor,
             would interfere with interpretation of subject safety or study results

          -  Concurrent enrollment in another clinical study

          -  Use of immunosuppressive medication within 3 months prior to screening

          -  Acute upper or lower respiratory infections requiring antibiotics or antiviral
             medications with in 30 days prior to screening or during screning period.

          -  Receipt of immunoglobulin or blood products within 30 days prior to screening or
             during the screening period

          -  Receipt of any investigational non-biological drug therapy within 30 days or 5
             half-lives prior to screening whichever is longer; or receipt of any marketed or
             investigational biologic within 6 months or 5 half-lives prior to screening whichever
             is longer

          -  Pregnant, lactating, or breastfeeding woman

          -  Diagnosis of lung disease other than persistent asthma

          -  History of smoking â‰¥10 pack years or any smoking within 12 months prior to screening

          -  History of active, infectious hepatitis A, B, C or human immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gossage, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>October 10, 2012</last_update_submitted>
  <last_update_submitted_qc>October 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

